Long-term functioning status of COVID-19 survivors: a prospective observational evaluation of a cohort of patients surviving hospitalisationObservational Study Published on 2022-07-272022-10-04 Journal: BMJ Open [Category] COVID19(2023년), SARS, 임상, [키워드] 24 hour activities acute SARS-CoV-2 infection age analogue Analysis Anxiety assessment Borg Brazil breathlessness Care chronic clinical manifestations cohort of patient COVID-19 daytime Depression disability fatigue functional Functional status handgrip strength hospital hospital discharge hospitalisation hospitalised illness Independence indicated Insomnia Insomnia Severity Index intake Invasive mechanical ventilation investigated Long-term condition measure Medical Research Council MOST MRC muscle oral Pain participant prevalent prospective observational study public health reduced rehabilitation medicine reported required scale schedule sleepiness Sociodemographic Stand strength survivor Survivors Test treat university hospital Visual weakness WHO [DOI] 10.1136/bmjopen-2021-057246 PMC 바로가기 [Article Type] Observational Study
Symptom-Based COVID-19 Prognosis through AI-Based IoT: A Bioinformatics ApproachAI 기반 IoT를 통한 증상 기반 코로나19 예후: 생물정보학 접근Article Published on 2022-07-232022-09-12 Journal: BioMed Research International [Category] MERS, 진단, [키워드] Accuracy approach automated booster Classifier Comparative analysis COVID COVID-19 COVID-19 prognosis disease health monitoring healthcare Healthcare professional Healthcare system help hospitalised IMPROVE Internet machine learning classifier machine learning model Pandemics Patient predict Predictive provide random reducing reported retrieved Support Symptom Symptoms the patient was measured [DOI] 10.1155/2022/3113119 PMC 바로가기 [Article Type] Article
An integrated analysis and comparison of serum, saliva and sebum for COVID-19 metabolomics Research Published on 2022-07-132022-10-05 Journal: Scientific Reports [Category] 바이오마커, 치료기술, 치료법, [키워드] alteration analysed Analysis biofluid Blood changes in Cohort correlation COVID-19 COVID-19 infection dominant dyslipidaemia hallmark hospitalised immunostimulatory Lipid majority metabolite metabolites metabolomics negative controls participant Pathologies pathophysiological conditions Patient performed plasma positive profile provided Saliva salivary Sebum sensitivity Sensitivity and specificity serum specificity Triglyceride utilised [DOI] 10.1038/s41598-022-16123-4 [Article Type] Research
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trialClinical Trial Published on 2022-07-082022-10-05 Journal: The Lancet. Respiratory Medicine [Category] 임상, 진단, 치료법, [키워드] 1:1 addition adverse event Analysis assigned baseline Cohort Complete COVID-19 cumulative defined double-blind Europe extracorporeal membrane oxygenation finding Follow-up funding hazard ratio hospital discharge hospitalised hypothesised IMPROVE incidence infused intravenous Invasive mechanical ventilation investigators modified intention-to-treat monoclonal antibody combination Mortality neutralising NIH occurred operation Organ failure outcome participant Patient Phase 3 phase 3 trial Placebo placebo group placebo-controlled trial Primary outcome randomised Randomly receive receiving Registered Remdesivir renal replacement therapy Result Safe seronegative Singapore speed standard care study drug Study participants Support sustained Symptom the placebo group therapy Treatment Uganda USA were excluded with COVID-19 [DOI] 10.1016/S2213-2600(22)00215-6 [Article Type] Clinical Trial
Does awake prone positioning prevent the use of mechanical respiratory support or death in COVID-19 patients on standard oxygen therapy hospitalised in general wards? A multicentre randomised controlled trial: the PROVID-19 protocol깨어 있는 엎드린 자세가 일반 병동에 입원한 표준 산소 요법을 받는 COVID-19 환자의 기계적 호흡 지원 또는 사망을 방지합니까? 다기관 무작위 대조 시험: PROVID-19 프로토콜Article Published on 2022-07-082022-09-11 Journal: BMJ Open [Category] COVID19(2023년), SARS, 임상, [키워드] acute respiratory distress acute respiratory distress syndrome approved ARDS Awake prone positioning body mass body mass index composite endpoint COVID-19 COVID-19 patient COVID-19 patients death death in COVID-19 decrease defined Ethics France hospitalised hypothesised hypoxaemia IMPROVE Infectious diseases Informed consent intervention group intubation investigator-initiated mechanical respiratory multicentre Non-intubated non-invasive ventilation Noninvasive ventilation Oxygenation Patient patients with ARDS peer-reviewed Prevent prone Prone position prone positioning protocol randomised randomised controlled receive registration number respiratory distress Respiratory distress syndrome respiratory infections responsible Safe severity Standard of care standard oxygen therapy Stratification submitted Support survival syndrome the ethics committee Treatment treatment failure Trial usual care usual care alone [DOI] 10.1136/bmjopen-2021-060320 PMC 바로가기 [Article Type] Article
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trialRandomized Controlled Trial Published on 2022-07-052022-10-05 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] 1:1 active against addition age Analysis assigned B.1.1.529 baseline Community Complete COVID-19 COVID-19 symptom COVID-19 vaccination COVID-19 vaccine death diagnostic dose double-blind drugs Efficacy Endpoint expected finding follow-up period funding Health healthy Hoffmann-La Roche hospitalised household contact immune response incidence infected individuals Infectious diseases investigator Local monoclonal antibody combination mounted occurred participant patient population Placebo placebo-controlled trial post-hoc post-hoc analysis prespecified analysis prevented prevention of COVID-19 Prophylaxis proportion provided randomisation randomised Randomly receive receiving reduced Regeneron Pharmaceuticals Registered reported risk of COVID-19 risk reduction Romania RT-PCR testing SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-infected individual Seroconversion seronegative seropositive shown single dose strain stratified subcutaneous injection susceptible symptomatic SARS-CoV-2 infection the placebo group timepoint treatment-emergent adverse event treatment-emergent adverse events uninfected unmet need USA variants waned [DOI] 10.1016/S1473-3099(22)00416-9 [Article Type] Randomized Controlled Trial
SARS-CoV-2 Spike- and Nucleoprotein-Specific Antibodies Induced After Vaccination or Infection Promote Classical Complement Activation예방 접종 또는 감염 후 유도된 SARS-CoV-2 스파이크 및 핵단백질 특이적 항체는 고전적 보체 활성화를 촉진합니다Article Published on 2022-07-042022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료법, 치료제, [키워드] activated Activation antibodies antibody Antibody responses Antigen binding C1q C1q binding C3b cascade classical classical pathway complement Complement activation Complement cascade complement components Complement pathway component components convalescent COVID-19 COVID-19 patient COVID-19 patients deposition disease status downstream Effect ELISA assay groups hospitalised IgG1 induced median N antigen NHC non-hospitalised non-infected not differ nucleocapsid presence of antibody protective role Protein Protein binding response responses SARS-CoV-2 SARS-CoV-2 antigens SARS-COV-2 infection SARS-CoV-2 protein SARS-CoV-2 proteins sera severe COVID-19 specific antigen spike spike glycoprotein subject the disease vaccination Vaccine vaccinees Variability Viral Viral antigen viral antigens [DOI] 10.3389/fimmu.2022.838780 PMC 바로가기 [Article Type] Article
Establishing COVID-19 trials at scale and pace: Experience from the RECOVERY trialResearch article Published on 2022-07-012022-10-05 Journal: Advances in biological regulation [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] Baricitinib benefit benefits of treatment common diseases COVID-19 COVID-19 therapy Dexamethasone drug enrolled Establishing evaluate experience hospitalised identify moderate numbers of patient pandemic Patient Randomised Evaluation recovery RECOVERY trial recruitment routine clinical care shown the SARS-CoV-2 Tocilizumab Treatment Trial with COVID-19 [DOI] 10.1016/j.jbior.2022.100901 [Article Type] Research article
Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study예방 접종 상태에 따른 SARS-CoV-2 델타 변이체 감염 후 소아에서 다기관 염증 증후군의 발병률 및 임상 표현형: 덴마크 전국 전향 코호트 연구Article Published on 2022-07-012022-09-11 Journal: The Lancet. Child & adolescent health [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] 95% CI B.1.617.2 Breakthrough infection calculated center children clinical phenotype Cohort cohort study comparable contribute Control COVID-19 Data collection delta variant Delta wave Denmark disease disease control education Effectiveness Factors higher education hospitalised incidence individual infected individuals Infection infection with SARS-CoV-2 Inflammatory Innovation MIS-C number of infected occur pandemic Patient phenotype Poisson regression population-based cohort prevention prospective cohort study rate ratio Registered Research SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 variant Science Surveillance syndrome the SARS-CoV-2 vaccinated individual vaccination Vaccination Status Vaccine variant variant of SARS-CoV-2 was obtained [DOI] 10.1016/S2352-4642(22)00100-6 PMC 바로가기 [Article Type] Article
Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study질병 진행 위험이 높은 경증에서 중등도 COVID-19 환자를 대상으로 한 다양한 단일 클론 항체 요법의 임상 효능: 전향적 코호트 연구Observational Study Published on 2022-07-012022-09-11 Journal: European Journal of Clinical Microbiology & Infect [Category] COVID19(2023년), SARS, 변종, 임상, 진단, 치료기술, [키워드] (alpha 95% CI 95% confidence interval adjusted odds ratio analysed anti-SARS-CoV-2 antibody treatment B.1.1.7 bamlanivimab Bamlanivimab-etesevimab, casirivimab-imdevimab baseline Baseline serology Casirivimab circulating variants clinical Clinical outcome clinical outcomes combination regimen conducted COVID-19 COVID-19 outpatient COVID-19 outpatients COVID-19 progression disease Efficacy eight etesevimab Factor groups high risk high-risk population hospital hospitalisation hospitalised Imdevimab Italian Logistic regression mAb Medicine Mild Mild-to-moderate Mild-to-moderate COVID-19 outpatients Moderate COVID-19 monoclonal antibodies monoclonal antibody Monoclonal antibody treatments Monoclonal antibody treatments for COVID-19 multivariable no significant difference no significant differences non-hospitalised Outpatient Patient patient subgroup patients progression proportion prospective cohort study Prospective Study Randomised trial randomised trials receiving regimen SARS-CoV-2 SARS-CoV-2 early treatments. SARS-CoV-2 vaccination SARS-CoV-2 variant serology significant differences significantly higher significantly lower The B.1.1.7 treated vaccination variant [DOI] 10.1007/s10096-022-04464-x PMC 바로가기 [Article Type] Observational Study